Search | Clinical Trials Finder

Conditions: Atrial Fibrillation
Interventions: Numeris-AF Tethered Coagulation System with VisiTrax; Device
Lead sponsor: nContact Surgical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Venice, Florida • Memphis, Tennessee

Conditions: Central Retinal Vein Occlusion
Interventions: Tissue Plasminogen Activator; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Deep Vein Thrombosis, Acute Pulmonary Embolism
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism), Rivaroxaban, Breastfeeding, Breast Milk Collection
Interventions: Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Raynaud Phenomenon Secondary to Systemic Sclerosis
Interventions: Placebo IV infusion, Iloprost Injection, for intravenous use; Drug
Lead sponsor: Civi Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 16
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more

Conditions: Pulmonary Embolism, Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Interventions: Catheter directed therapy, Systemic anticoagulation; Device · Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Saphenous Vein Graft Disease, Myocardial Ischemia, Embolism
Interventions: FiberNet EPS used during SVG intervention.; Device
Lead sponsor: Lumen Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Ocala, Florida • Indianapolis, Indiana • Royal Oak, Michigan + 3 more

Conditions: Pulmonary Embolism
Interventions: Blood sample; Genetic
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2035
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Blood Loss, Surgical
Interventions: Quantra System; Diagnostic Test
Lead sponsor: HemoSonics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin; Drug
Lead sponsor: Cogentus Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 247
States / cities: Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more

Conditions: Venous Thrombosis, Pulmonary Embolism
Interventions: Fondaparinux Sodium; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Macular Edema
Interventions: Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone; Device · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more

Conditions: Venous Thromboembolism
Interventions: Semuloparin Sodium, Enoxaparin sodium, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 4,413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 25
States / cities: Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more

Conditions: Thrombosis
Interventions: BMS-986141, Aspirin, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 21 more

Conditions: Raynaud's Phenomenon
Interventions: nitroglycerin 0.9 % (MXQ-503), Nitroglycerin ointment 2%, USP; Drug
Lead sponsor: MediQuest Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Heart Defects, Congenital
Interventions: Clopidogrel (SR25990), placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: Up to 92 Days
Enrollment: 906 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Branch Retinal Vein Occlusion
Interventions: pegaptanib sodium (Macugen); Drug
Lead sponsor: Palmetto Retina Center, LLC; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina

Conditions: Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions: Edoxaban, Standard of Care; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 1 Day to 17 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more

Conditions: Retinal Vein Occlusion
Interventions: pegaptanib sodium; Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 35
States / cities: Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more

Conditions: Total Knee Replacement, Venous Thromboembolism
Interventions: Measurement of total thrombolic load; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Heparin Induced Thrombocytopenia (HIT)
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Education; Other
Lead sponsor: Mercy Health Ohio; Other
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Youngstown, Ohio

Conditions: Coronary Disease
Interventions: rNAPc2; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: CAY001, Placebo; Drug · Other
Lead sponsor: Cayuga Biotech, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Search by objective public record fields.

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

Registry of Patients Prescribed Anticoagulation

Excretion of Rivaroxaban in Human Breast Milk

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Ventilation and Perfusion Scan in Pulmonary Embolism Following Catheter Directed Thrombectomy Versus Anticoagulation Alone

The RETRIEVE Study: Use of the FiberNet® Embolic Protection System in Saphenous Vein Grafts

Genetic Markers of Patients With History of Pulmonary Embolism Post Total Joint Arthroplasty

Pre-surgical Evaluation for the Quantra System in Adult Patients Undergoing Cardiac Surgery

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Total Knee Arthroplasty And Thromboembolism: A Comparison Between Two Surgical Techniques

Heparin Induced Thrombocytopenia: Pharmacoeconomics

Bedside Ultrasound in the Assessment of Deep Venous Thrombosis: Effectiveness of In-Person Versus Online Instruction

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

Study to Evaluate CAY001 in Healthy Volunteers